Smallpox
📧 Sign up to get email alerts when something new happens for Smallpox.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-07EMA Authorised: Imvanex (modified vaccinia Ankara - Bavarian Nordic (MVA-BN) virus) — Bavarian Nordic A/S
EMA has authorised Imvanex (MVA-BN) vaccine from Bavarian Nordic A/S for smallpox and monkeypox indications.
-
EMA approval · 2026-06-15EMA Authorised: Tecovirimat SIGA (tecovirimat) — SIGA Technologies Netherlands B.V.
The EMA authorized tecovirimat (SIGA) for multiple poxvirus infections, including monkeypox and smallpox, under the marketing authorization …
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS [Phase 2]
A Phase 2 clinical trial update evaluating safety and immunogenicity of oral tecovovirmat (TPOXX) given for 28 days in combination with the …
-
CLINICAL_TRIALS trial_result · 2026-03-04Clinical Trial Update: A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa [Phase 2]
Ongoing Phase 2 randomized trial evaluating the safety, reactogenicity, and immunogenicity of an mRNA-based Mpox vaccine candidate in Africa…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BSY001 After Single/Multiple Doses. [Phase 1]
Early-phase Phase 1 trial to evaluate the safety, tolerability, and pharmacokinetics of BSY001 after single and multiple doses; currently re…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-11-24Clinical Trial Update: Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections [Phase 2]
An open-label Phase 2 multicenter immunogenicity and safety study evaluating the MVA-BN vaccine in children aged 2 to under 12 years, compar…
-
EMA approval · 2025-11-10EMA Authorised: Tecovirimat SIGA (tecovirimat) — SIGA Technologies Netherlands B.V.
The EMA authorised tecovirimat (brand SIGA) for treatment of orthopoxvirus infections including cowpox, monkeypox, vaccinia infection, and s…
-
EMA approval · 2025-10-20EMA Authorised: Imvanex (modified vaccinia Ankara - Bavarian Nordic (MVA-BN) virus) — Bavarian Nordic A/S
EMA authorised Imvanex (MVA-BN) from Bavarian Nordic A/S for protection against smallpox and monkeypox, expanding its indications to include…
-
CLINICAL_TRIALS research · 2025-10-16Clinical Trial Update: Evaluating the Human Immune Response to the JYNNEOS Vaccine [EARLY_Phase 1]
Early-phase trial evaluating the human immune response to the JYNNEOS vaccine. The study status is Active Not Recruiting.
-
CLINICAL_TRIALS trial_result · 2025-10-08Clinical Trial Update: VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection
The document provides an update on the VA-005 trial evaluating vaccinia immune globulin intravenous (VIGIV) for treating complications of sm…
-
CLINICAL_TRIALS trial_result · 2025-09-19Clinical Trial Update: MVA Post-Event: Administration Timing and Boost Study [Phase 1, Phase 2]
A Phase 1/2 clinical trial update evaluating the timing of post-exposure MVA vaccination and booster dosing for smallpox, with results poste…
-
CLINICAL_TRIALS trial_result · 2025-07-16Clinical Trial Update: A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age [Phase 1, Phase 2]
The study reports the completion of a Phase 1/2 trial evaluating the safety, tolerability, and immune response of multiple doses of the inve…
-
CLINICAL_TRIALS trial_result · 2025-06-13Clinical Trial Update: High Dose IMVAMUNE® in Vaccinia-Naive Individuals [Phase 2]
Phase 2 trial evaluating a high-dose IMVAMUNE smallpox vaccine in vaccinia-naive adults; results were posted in 2025.
-
CLINICAL_TRIALS trial_result · 2025-03-06Clinical Trial Update: Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure
Clinical trial update for the antiviral Tecovirimat (ST-246) used to treat exposure to orthopoxviruses, including smallpox and monkeypox; th…
-
CLINICAL_TRIALS trial_result · 2025-01-15Clinical Trial Update: Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults [Phase 1]
A Phase 1 study assessing the bioequivalence of Brincidofovir Form H and Form II tablets in healthy adults has completed.
-
CLINICAL_TRIALS trial_result · 2024-10-23Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days [Phase 3]
Phase 3 trial assessing the safety, tolerability, and pharmacokinetics of orally administered tecovirimat (TPOXX) over 28 days for smallpox;…
-
CLINICAL_TRIALS trial_result · 2024-10-09Clinical Trial Update: Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders [Phase 4]
Phase 4 study evaluating drug-drug interactions between TPOXX (tecovirimat) and phosphate binders has completed and results were posted.
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG [Phase 4]
Phase 4 study evaluating safety, tolerability, and pharmacokinetics of tecovirimat (TPOXX) in adults weighing more than 120 kg with smallpox…
-
FDA approval · 2024-06-03FDA Approved: TPOXX — Supplemental Application (SIGA Technologies, Inc.)
FDA approves a supplemental application for TPOXX (tecovirimat monohydrate) from SIGA Technologies, expanding its approved use for smallpox.
-
FDA approval · 2024-06-03FDA Approved: TPOXX — Supplemental Application (SIGA Technologies, Inc.)
FDA approved a supplemental application for TPOXX (tecovirimat monohydrate) submitted by SIGA Technologies, Inc. The supplement has been app…
-
CLINICAL_TRIALS trial_result · 2023-05-06Clinical Trial Update: Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years [Phase 2, Phase 3]
Phase 2/3 trial evaluating immunogenicity, reactogenicity, and safety of the VACΔ6 vaccine in adults 18-60; study completed.
-
FDA approval · 2022-05-18FDA Approved: TPOXX — Original Application (SIGA Technologies, Inc.)
The FDA approved TPOXX (tecovirimat monohydrate) from SIGA Technologies under original NDA 214518 for the treatment of smallpox in adults an…
-
FDA approval · 2022-05-18FDA Approved: TPOXX — Supplemental Application (SIGA Technologies, Inc.)
The FDA approved a supplemental application for TPOXX (tecovirimat monohydrate) submitted by SIGA Technologies, Inc. The action updates the …
-
FDA approval · 2021-08-03FDA Approved: TEMBEXA — Supplemental Application (Emergent BioDefense Operations Lansing LLC)
FDA approved a supplemental application for TEMBEXA (brincidofovir) submitted by Emergent BioDefense Operations Lansing LLC.
-
FDA approval · 2021-06-04FDA Approved: TEMBEXA — Original Application (Emergent BioDefense Operations Lansing LLC)
FDA approved TEMBEXA (brincidofovir) under the original NDA (NDA214460) for the treatment of smallpox (Variola virus), developed by Emergent…